Since STING agonist-associated treatment benefits occur in association with non-classical/immature TLS formation, with seemingly minimal input from B cells, these findings also reenergize discussions related to the operational importance of B cells in therapeutic anti-tumor immune responses. Here, STING1 is linked to neoplasm.